Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ (The Korean Society Nonclinical Study)-KSNS

ÇмúÇà»ç

·Î±×ÀÎ ¾ÆÀ̵ð ±â¾ï
 
ÇмúÇà»ç¸ñ·Ï Home > ÇмúÇà»ç > ÇмúÇà»ç¸ñ·Ï
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2015³â Á¦28Â÷ Workshop °³ÃÖ ¾È³»
ÀÛ¼ºÀÚ °ü¸®ÀÚ email http://www.nonclinical.or.kr
Date2015³â 09¿ù 14ÀÏ 10:21Hits5060
÷ºÎÆÄÀÏ ¡Ø ÇöÀç DB¿¡´Â ÆÄÀÏÁ¤º¸°¡ ÀÖÀ¸³ª, FTP »ó¿¡ ÆÄÀÏÀÌ Á¸ÀçÇÏÁö ¾Ê½À´Ï´Ù.
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2015³â Á¦28Â÷ Workshop °³ÃÖ ¾È³»
"Risk Mitigation Strategies in Drug Discovery and Development"
2015³â 10¿ù 15ÀÏ(¸ñ)~16ÀÏ(±Ý) / ¿©ÁÖ ½ã¹ë¸®
(»çÀüµî·Ï ¸¶°¨ : ~ 10¿ù 12ÀÏ (¿ù) 18½Ã ±îÁö)

¡á Çà»ç°³¿ä

Çà»ç¸í Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2015³â Á¦28Â÷ Workshop
ÁÖÁ¦ Risk Mitigation Strategies in Drug Discovery and Development
ÀϽà 2015³â 10¿ù 15ÀÏ(¸ñ)~16ÀÏ(±Ý)
Àå¼Ò ¿©ÁÖ ½ã¹ë¸® (ÁÖ¼Ò : °æ±âµµ ¿©Áֽà °­º¯À¯¿øÁö±æ 45 (¿¬¾çµ¿ 414))
´Ù¿î·Îµå °ø¹® - Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ Á¦28Â÷ ¿öÅ©¼¥ °³Ã־ȳ»
¹®ÀÇ ±âŸ ¹®ÀÇ»çÇ×Àº Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
ÀüÈ­ : 031-706-2995, E-mail : ksns@nonclinical.or.kr, °íÁ¾È­

¡á µî·Ï ¾È³»

- »çÀüµî·Ï ¾È³»
µî·Ï±â°£ - ~ 2015³â 10¿ù 12ÀÏ (¿ù) 18½Ã ±îÁö
µî·Ï¹æ¹ý - ¿¬±¸È¸ ȨÆäÀÌÁö (www.nonclinical.or.kr) ÇмúÇà»ç > »çÀüµî·Ï ¸Þ´º ÀÌ¿ë
- ºñȸ¿øÀº ȸ¿ø°¡ÀÔ ÈÄ, »çÀüµî·ÏÀÌ °¡´ÉÇÕ´Ï´Ù.
- µî·Ïºñ
µî·Ïºñ ±¸ºÐ »çÀüµî·Ï ÇöÀåµî·Ï
Á¤È¸¿ø 100,000 ¿ø 150,000 ¿ø
Çлýȸ¿ø 60,000 ¿ø 100,000 ¿ø
  • »çÀüµî·Ïºñ : ÀÚ·áÁý, ¼ö·áÁõ, ¼÷¹Ú(4ÀÎ/1½Ç), ½Äºñ Æ÷ÇÔ
  • ¼¼±Ý°è»ê¼­ ¹ß±Þ(ÀÔ±ÝÀÏ ±âÁØ 1ȸ ¹ß±Þ)ÀÌ ÇÊ¿äÇÒ °æ¿ì, ¿Â¶óÀÎ µî·Ï¶§ ¼¼±Ý°è»ê¼­ ¹ßÇàÇà¿©ºÎ¸¦ üũÇϰí, »ç¾÷ÀÚµî·ÏÁõ »çº»À» ¹Ýµå½Ã ÷ºÎ
  • ÇöÀåµî·Ï ¹× Çлýµî·ÏÀÇ °æ¿ì, ¼¼±Ý°è»ê¼­ ¹ß±Þ ºÒ°¡, ¿¬±¸È¸ ÀÚü ¿µ¼öÁõ ¹ß±Þ
- ¹«ÅëÀåÀÔ±Ý (°èÁÂÀÌü)
ÀԱݰèÁ - ¿ì¸®ÀºÇà 1005-101-920320 ¢ß Å¥º£½ºÆ®ÄÁ¼³ÆÃ ºñÀӻ󿬱¸È¸
ÀԱݸ¶°¨ - ~ 2015³â 10¿ù 13ÀÏ (È­) 18½Ã ±îÁö
  • ÀԱݽà ¹Ýµå½Ã "¼Ò¼Ó/¼º¸í" À» ±âÀÔÇϼ¼¿ä.
  • ¹«ÅëÀå ÀÔ±Ý(°èÁÂÀÌü)ÀÌü ÈÄ, »ç¹«±¹¿¡¼­ ÀÔ±ÝÀ» È®ÀÎÇÏ´Â ½Ã°£ÀÌ 1ÀÏÁ¤µµ ¼Ò¿ä µË´Ï´Ù.
  • ½Å¿ëÄ«µå °áÁ¦´Â ºÒ°¡´É ÇÕ´Ï´Ù.
  • ±âŸ µî·Ï °ü·Ã ¹®ÀÇ»çÇ×Àº Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
    TEL. 031-706-2995, E-mail. ksns@nonclinical.or.kr, °íÁ¾È­

¡á ÇÁ·Î±×·¥ ¾È³» 


Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸Á¦28Â÷ WORKSHOP Program

  1. ³¯Â¥: 2015³â 10¿ù 15-16ÀÏ (¸ñ-±Ý)
  2. Àå¼Ò: ¿©ÁÖ ½ã¹ë¸®È£ÅÚ (°æ±âµµ ¿©Áֽà °­º¯À¯¿øÁö±æ 45)
  3. ÁÖÁ¦: Risk Mitigation Strategies in Drug Discovery and Development

Time PROGRAM
Day 1 October 15, 2015 (Thursday), 2Ãþ ±×·£µåº¼·ë
10:00-11:00 Registration
11:00-11:10 Opening (±èµ¿È¯ ȸÀå)
  Key note lecture
11:10-12:00 Innovative innovation in drug discovery (Çѱ¹È­Çבּ¸¿ø ÇÏÀçµÎ ¹Ú»ç)
12:00-12:45 Luncheon symposium (Sponsor: ¹ÙÀÌ¿ÀÅå½ºÅØ "¹Ì±¹ FDA Àû°Ý½ÂÀÎÀÇ ÀǹÌ" °­Á¾±¸ ´ëÇ¥)
12:45-13:30 Booth Exhibition & Coffee Break
3Ãþ ¼¼Á¾È¦
Session 1 Hot topics and emerging technologies for drug development (ÁÂÀå: Àϵ¿Á¦¾à ¹Ú¼öºÀ ¹Ú»ç)
13:30-14:15 Hot topics in non-clinical safety assessment of biologics (EnVigo, Mr. Lee Coney)
14:15-15:00 Responses to the standard for exchange of nonclinical data (SEND) in non-US countries;
accelerate your nonclinical data submission in US and Japan (Showa University, Dr. Takayuki Anzai)
15:00-15:20 Booth Exhibition & Coffee Break
3Ãþ ¼¼Á¾È¦
15:20-16:05 Humanized-knockout zebrafish for disease models (Ãæ³²´ë ±èöÈñ ±³¼ö)
16:05-16:50 SYK inhibitor for treatment of rheumatoid arthritis (¿À½ºÄÚÅØ, ±èÁßÈ£ ¹Ú»ç)
16:50-17:35 Clinical application of immune checkpoint blockers into cancer immunotherapy (¿¬¼¼´ë ÇÏ»óÁØ ±³¼ö)
17:40-18:00 Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ ÃÑȸ
18:00-20:00 Dinner & Social networking (¾ß¿Ü BBQ ¿¹Á¤)
Day 2 October 16, 2015 (Friday)
07:00-09:00 Breakfast
Session 2 µ¶¼ººÐ°ú
(ÁÂÀå: ÇÑÈ­, °í¿ì¼® ¹Ú»ç)
3Ãþ »çÆÄÀ̾î·ë
Translation of nonclinical data for clinical development
¾àµ¿·ÂÇкаú
(ÁÂÀå: µ¿¾Æ ST, ½ÉÇöÁÖ ¹Ú»ç)
3Ãþ Å©¸®½ºÅ»·ë

Various risk mitigation strategies of PK studies
¾àÈ¿¾à¸®ºÐ°ú
(ÁÂÀå: Çö´ë¾àǰ, ±è´ëÈÆ ¹Ú»ç)
2Ãþ ±×·£µåº¼·ë

Pharmacological approaches to reduce the drug development attrition
09:00-09:40 ¹ÙÀÌ¿ÀÀǾàǰ °³¹ßÀ» À§ÇÑ Àü·«Àû TCR Ȱ¿ë
(¼­¿ï´ë/¿¡À̺ñ¿Â ½Å¿µ±â ±³¼ö)
PK parameterÀÇ ½ÇÁ¦Àû ÇØ¼®: The basics and beyond
(C&C½Å¾à¿¬±¸¼Ò ±èÀ¯Ã¶ ¹Ú»ç)
In vivo evaluation of specific gene functions in dilated cardiomyopathy and cancer
(¿¬¼¼´ë, ÀÌÇÑ¿õ ±³¼ö)
09:40-10:20 Selection of the maximum recommended starting dose in first-in-human studies with biologics
(¼­¿ï´ë, ÀÌÇü±â ±³¼ö)
Practical considerations for successful quantitative bioanalysis
(¹ÙÀÌ¿ÀÄÚ¾Æ, ÀÌÈñÁÖ ¹Ú»ç)
LC compounds as selective and efficacious oral proteasome inhibitors for multiple myeloma patients
(LG »ý¸í°úÇÐ, ¹Ú¾ï ¿¬±¸¿ø)
10:20-10:40 Booth Exhibition & Coffee Break
3Ãþ ¼¼Á¾È¦
10:40-11:20 ÀÓ»ó½ÃÇè ½ÂÀÎÀ» À§ÇÑ ºñÀÓ»ó½ÃÇè °í·Á»çÇ× (»ç·ÊÁß½É)
(½Ä¾àó, ¹ÚÀçÇö¿¬±¸°ü)
IVIVC ¸ðµ¨¸µÀ» ÀÌ¿ëÇÑ ¹æÃâÁ¦¾î Á¦ÇüÀÇ ¼³°è
(¼º±Õ°ü´ë, ±èÅÂȯ ¹Ú»ç)
New drug development of a novel transient potential vanilloid type 1 (TRPV1) channel antagonist for atopic dermatitis
(¾Æ¸ð·¹ÆÛ½ÃÇÈ, ¹Ú¹Ì¿µ ¹Ú»ç)
11:20-12:00 GLP µ¶¼º½ÃÇè¿¡ À־ ºÐ¼®½ÃÇèÀÇ °³¿ä ¹× SponsorÀÇ °í·Á»çÇ×
(KIT, Ȳ°æÈ­ ¹Ú»ç)
¹æ»ç¼±µ¿À§¿ø¼Ò Ç¥Áö¹°ÁúÀ» ÀÌ¿ëÇÑ ÀüÀÓ»ó ADME ¿¬±¸½ÃÀÇ
°í·Á»çÇ×
(ÇѾç´ë À¯ÇýÇö ±³¼ö)
Preclinical models and strategies for development of medical products targeting GI disease
(NCEED, À̵·Çà ±³¼ö)
12:00-12:45 Luncheon symposium (Sponsor TS Dyne)
2Ãþ ±×·£µå º¼·ë
12:45-13:30 Booth Exhibition & Coffee Break
3Ãþ ¼¼Á¾È¦
Session 3 Drug discovery and development: Successful case studies (ÁÂÀå: º¸·ÉÁ¦¾à ±è´ÞÇö ¹Ú»ç)
2Ãþ ±×·£µåº¼·ë
13:30-14:15 Development strategy of an orally active drug candidate, EC-18 for chemotherapy-induced neutropenia
(¿£ÁöÄÍ, ÇÑ¿ëÇØ ¹Ú»ç)
14:15-14:30 °æÇ°Ãßõ & Closing (ÀÌ»óÈ£ ºÎȸÀå)
- »ó±â ÇÁ·Î±×·¥Àº ¿¬ÀÚ ¹× ±âŸ »çÁ¤À¸·Î º¯µ¿ ¼ö ÀÖ½À´Ï´Ù.

¡á ¿©ÁÖ ½ã¹ë¸® ã¾Æ¿À½Ã´Â ±æ

ÁÖ¼Ò °æ±âµµ ¿©Áֽà °­º¯À¯¿øÁö±æ 45 (¿¬¾çµ¿ 414)
- [³×À̹ö Áöµµ]·Î À§Ä¡ È®ÀÎ ¹× ±³Åë Âü°í :
ȨÆäÀÌÁö www.yeojusunvalley.co.kr




List
°³ÀÎÁ¤º¸Ãë±Þ¹æÄ§
(ÁÖ)µå¸²ÆÄÆ®³Ê (»ç¾÷ÀÚµî·Ï¹øÈ£ : 320-88-00843, ´ëÇ¥ : ±è»ó¿ì)
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ (The Korean Society Nonclinical Study)
(¿ì)446-982 °æ±âµµ ¿ëÀνà ±âÈﱸ Èï´öÁß¾Ó·Î 120 U-TOWER 1411È£
Tel : 031-702-9123 , Fax : 031-213-9125, E-Mail : ksns@nonclinical.or.kr
Copyright & "The Korean Society Nonclinical Study". Website development and maintenance: "Expedition". All Rights Reserved.